- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06897930
En studie för att undersöka säkerheten, tolerabiliteten och effekten av AZD0120 hos vuxna med eldfast SLE
En fas 1B/2-studie av AZD0120, en chimär antigenreceptor T-cell (CAR T) terapi som riktar sig till CD19 och B-cellmognadsantigen (BCMA) hos personer med eldfast systemisk lupus erythematosus (SLE)
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study will enrol adult participants with refractory Systemic Lupus Erythematosus (SLE) The study will be run in 2 parts;
First part is Phase 1b during which the study aims to assess safety and tolerability of AZD0120 in patients in refractory SLE cohorts
Second part is Phase 2, during which the study aims to assess safety, tolerability and efficacy of the selected dose, following Phase 1b completion, in patients with refractory SLE
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studieorter
-
-
-
Darlinghurst, Australien, 2010
- Rekrytering
- Research Site
-
Melbourne, Australien, 3000
- Rekrytering
- Research Site
-
-
-
-
California
-
San Francisco, California, Förenta staterna, 94143
- Rekrytering
- Research Site
-
Stanford, California, Förenta staterna, 94304-2201
- Indragen
- Research Site
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Indragen
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Research Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Har inte rekryterat ännu
- Research Site
-
Bethesda, Maryland, Förenta staterna, 20892
- Indragen
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Research Site
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Rekrytering
- Research Site
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Rekrytering
- Research Site
-
Syracuse, New York, Förenta staterna, 13202-2240
- Rekrytering
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599-7280
- Rekrytering
- Research Site
-
Charlotte, North Carolina, Förenta staterna, 28204
- Rekrytering
- Research Site
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298
- Har inte rekryterat ännu
- Research Site
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- Rekrytering
- Research Site
-
Seattle, Washington, Förenta staterna, 98195
- Rekrytering
- Research Site
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5T 2S8
- Indragen
- Research Site
-
-
-
-
-
Bristol, Storbritannien, BS1 3NU
- Indragen
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
INCLUSION:
- Males or females aged 18 through 70 years inclusive at the time of consent.
- Written informed consent in accordance with federal, local, and institutional guidelines.
- Must be able and willing to adhere to the study visit schedule and other protocol requirements
- Adequate hepatic, renal, pulmonary, and cardiac function
- Have a clinical diagnosis of SLE according to the EULAR/ American College of Rheumatology (ACR) 2019 criteria with a positive ANA ≥1:80 and a score ≥10.
- Have used at least two standard immunosuppressants (including one biological agent).
- SLEDAI-2K score ≥6 at screening.
- Must include a significant SLE related organ involvement: arthritis, myositis, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, vasculitis, or renal.
- For lupus nephritis: Diagnosis of proliferative lupus nephritis based on a renal biopsy obtained within 6 months prior to signing the informed consent form or during the screening period Class III, IV or V LN according to the WHO 2003 ISN/RPS classification.
EXCLUSION:
- Have received prior treatment with CAR T therapy directed at any target.
- Have received any therapy that is targeted to CD19 and/or BCMA
- Received allogenic stem cell transplant or autologous stem cell transplant.
- An active malignancy that is progressing or requires active treatment.
- Primary immunodeficiency
- Active viral or bacterial infection
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: AZD0120
Single dose of AZD0120 |
Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
Andra namn:
Lymphodepletion - specified dose prior to receiving AZD0120 Lymphodepletion - specified dose prior to receiving AZD0120 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)
Tidsram: 2 years
|
The incidence and severity of adverse events (AEs) |
2 years
|
|
PHASE 1B: Recommended Phase 2 Dose (RP2D) of AZD0120 in for Phase 2
Tidsram: 2 years
|
To determine the recommended phase 2 dose (RP2D) of AZD0120 |
2 years
|
|
PHASE 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Proportion of participants achieving SRI-4 response |
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Proportion of participants achieving SLE Responder Index 4 (SRI-4) response over time |
2 years
|
|
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Proportion of participants achieving remission in SLE (DORIS) remission over time |
2 years
|
|
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Proportion of participants achieving Lupus Low Disease Activity State (LLDAS) over time |
2 years
|
|
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Proportion of participants achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response over time |
2 years
|
|
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Time from AZD0120 infusion and time from response to first disease flare |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
The area under the concentration-time curve (AUC) from time zero (T0) to the last measurable concentration time point (AUClast) |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D)) |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
The last measurable concentration of AZD0120 (Clast) |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Maximum observed blood concentration (Cmax) |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Terminal half-life of a drug during its elimination phase in pharmacokinetics (t1/2λz) |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Time of the last measurable (quantifiable) concentration of a AZD0120 (Tlast) |
2 years
|
|
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Time of maximum observed blood concentration (Tmax) |
2 years
|
|
PHASE 1B & 2: To assess immunogenicity of AZD0120
Tidsram: 2 years
|
Presence of AZD0120 antibodies |
2 years
|
|
PHASE 1B & 2: To determine whether replication-competent lentivirus is present in participants that receive AZD0120
Tidsram: 2 years
|
Presence of replication-competent lentivirus (RCL) |
2 years
|
|
PHASE 2: To further characterize the safety of AZD0120 in participants with refractory SLE
Tidsram: 2 years
|
Further characterization of the safety of AZD0120 by measuring the incidence and severity of Treatment Emergent Adverse Events (TEAEs) |
2 years
|
|
PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status
Tidsram: 2 years
|
To assess changes from baseline for Changes in Lupus Quality of life (LupusQoL) |
2 years
|
|
PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status
Tidsram: 2 years
|
To assess changes from baseline for FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT) |
2 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Bindvävssjukdomar
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Glomerulonefrit
- Nefrit
- Hud- och bindvävssjukdomar
- Lupus erythematosus, systemisk
- Lupus nefrit
- Organiska kemikalier
- Kolväten
- Fosforamidsen
- Kväve senapsföreningar
- Senapsföreningar
- Kolväten, halogenerad
- Fosforamider
- Organofosforföreningar
- Cyklofosfamid
- fludarabin
Andra studie-ID-nummer
- D8313C00001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .